ArticleNature communications2021
Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy.
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 62 citations in OpenAlex.
- Somatostatin Receptor Expression and Theranostic Applications Across Non-Neuroendocrine Tumors: A Molecular-to-Clinical Review.International journal of molecular sciences · 2026Review
- The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression.Cancer medicine · 2026Article
- T cell fate regulation in EBV‑associated nasopharyngeal carcinoma (Review).Oncology reports · 2026Review
- SSTR2 expression in EBV-positive and EBV-negative lymphomas.Journal of hematopathology · 2026Article
- Regulation of calcium homeostasis by S100A12 drives NETosis in chronic kidney disease.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- SSTR2-targeting therapy in EBV-positive and EBV-negative metastatic nasopharyngeal carcinoma.American journal of cancer research · 2026Article
- Role of somatostatin receptor 2 (SSTR2) in pituitary adenomas.Clinical and translational medicine · 2025Article
- Integrating transcriptomics and hybrid machine learning enables high-accuracy diagnostic modeling for nasopharyngeal carcinoma.Discover oncology · 2025Article
- Mitochondrial function changes in T cell subsets during radiotherapy for patients with nasopharyngeal carcinoma.Oncology letters · 2025Article
- Comparison ofScientific reports · 2025Article
- Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: A pathologist's perspective.Brain pathology (Zurich, Switzerland) · 2025Review
- Development of [European journal of nuclear medicine and molecular imaging · 2024Article
- Metachronous Second Primary in the Form of Nasopharyngeal Carcinoma Following Treatment of Small Cell Neuroendocrine Carcinoma of the Head and Neck: Dual Tracer PET/CT Findings Highlighting SSTR2 Expression and Its Theranostic Implications.World journal of nuclear medicine · 2024Article
- SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma.Journal of clinical pathology · 2024Article
- Octreotide attenuates intestinal barrier damage by maintaining basal autophagy in Caco2 cells.Molecular medicine reports · 2024Article
- The landscape of cancer-rewired GPCR signaling axes.Cell genomics · 2024Article
- Synthesis and Evaluation of [ACS omega · 2024Article
- Design, Preclinical Evaluation, and Clinical Translation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Top IHC/ISH Hacks for and Molecular Surrogates of Poorly Differentiated Sinonasal Small Round Cell Tumors.Head and neck pathology · 2024Review
- GNA14 may be a potential prognostic biomarker in nasopharyngeal carcinoma.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
72 authors at 20 institutions in 10 countries.
Matt LechnerUCL Cancer Institute, University College London, London, UK. m.lechner@ucl.ac.uk.ORCID 0000-0002-7123-0773
Volker H SchartingerDepartment of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria.ORCID 0000-0002-5887-7644
Christopher D SteeleUCL Cancer Institute, University College London, London, UK.
Wen Long NeiDivisions of Radiation Oncology and Medical Sciences, National Cancer Centre, Singapore, Singapore.ORCID 0000-0001-6027-1652
Marc Lucas OoftKing´s College Hospitals, NHS Foundation Trust, London, UK.
Liesa-Marie SchreiberInstitute of Virology and Christian Doppler Laboratory for Viral Immunotherapy of Cancer, Medical University of Innsbruck, Innsbruck, Austria.
Christodoulos P PipinikasUCL Cancer Institute, University College London, London, UK.
Grace Tin-Yun ChungDepartment of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Yuk Yu ChanDepartment of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Feng WuDepartment of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Ka-Fai ToDepartment of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0003-4919-3707
Chi Man TsangDepartment of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.
Wayne PearceUCL Cancer Institute, University College London, London, UK.
Daniele MorelliUCL Cancer Institute, University College London, London, UK.
Martin PhilpottBotnar Research Centre, University of Oxford, Oxford, UK.
Liam MastersonDepartment of Otolaryngology, Addenbrooke's Hospital, Cambridge, UK.
Reshma NibhaniBotnar Research Centre, University of Oxford, Oxford, UK.
Graham WellsBotnar Research Centre, University of Oxford, Oxford, UK.
Christopher G BellWilliam Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.ORCID 0000-0003-4601-1242
Julia KollerDepartment of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria.
Susanne DelecluseGerman Cancer Research Centre (DKFZ) and Inserm, Unit F100/U1074, Heidelberg, Germany.
Yim Ling YipSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.ORCID 0000-0003-1574-8022
Jacklyn LiuUCL Cancer Institute, University College London, London, UK.
Cillian T FordeRoyal National Throat, Nose and Ear Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK.ORCID 0000-0003-2017-2056
Martin D ForsterUCL Cancer Institute, University College London, London, UK.
Amrita JayDepartment of Histopathology, University College London Hospitals NHS Trust, Euston Road, London, UK.
József DudásDepartment of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria.
Annika KrappDepartment of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria.
Simon WanInstitute of Nuclear Medicine, University College Hospital, Euston Road, London, UK.
Christian UprimnyDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Susanne SprungDepartment of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.
Johannes HaybaeckDepartment of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Innsbruck, Austria.
Tim R FentonSchool of Biosciences, University of Kent, Canterbury, UK.ORCID 0000-0002-4737-8233
Kerry ChesterUCL Cancer Institute, University College London, London, UK.
Christina ThirlwellUCL Cancer Institute, University College London, London, UK.
Gary RoyleUCL Cancer Institute, University College London, London, UK.
Teresa MarafiotiUCL Cancer Institute, University College London, London, UK.
Rajeev GuptaUCL Cancer Institute, University College London, London, UK.ORCID 0000-0001-9573-0505
Sagung Rai IndrasariENT Head and Neck Surgery Department, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia.
Camelia HerdiniENT Head and Neck Surgery Department, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia.
Mohd Afiq Mohd SlimDepartment of Ear, Nose and Throat, University Hospital Crosshouse, Crosshouse, Kilmarnock, UK.ORCID 0000-0002-6835-1304
I IndrawatiDepartment of Anatomical Pathology, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia.
Liam SuttonBarts Health NHS Trust, London, UK.
Renske FlesDepartment of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Bing TanENT Head and Neck Surgery Department, Universitas Gadjah Mada, Dr. Sardjito Hospital, Yogyakarta, Indonesia.
Joe YeongDepartment of Anatomical Pathology, Singapore General Hospital, Singapore, Singapore.
Amit JainDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Shuting HanDivision of Medical Oncology, National Cancer Centre, Singapore, Singapore.
Haitao WangDivisions of Radiation Oncology and Medical Sciences, National Cancer Centre, Singapore, Singapore.ORCID 0000-0001-6910-974X
Kelvin S H LokeDepartment of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore, Singapore.
Wan HeDepartment of Oncology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong, China.
Ruilian XuDepartment of Oncology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong, China.
Hongtao JinDepartment of Pathology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong, China.
Zhiqiang ChengDepartment of Pathology, The Second Clinical Medical College, Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong, China.
David HowardRoyal National Throat, Nose and Ear Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK.
Peter H HwangDepartment of Otolaryngology-Head and Neck Surgery, Stanford University School of Medicine, Palo Alto, CA, USA.
Quynh-Thu LeDepartment of Radiation Oncology, Stanford University School of Medicine, Palo Alto, CA, USA.
Joshua K TayDepartment of Pathology, Stanford University School of Medicine, Palo Alto, CA, USA.
Robert B WestDepartment of Pathology, Stanford University School of Medicine, Palo Alto, CA, USA.
Sai Wah TsaoSchool of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China.
Tim MeyerUCL Cancer Institute, University College London, London, UK.
Herbert RiechelmannDepartment of Otorhinolaryngology, Medical University of Innsbruck, Innsbruck, Austria.
Udo OppermannBotnar Research Centre, University of Oxford, Oxford, UK.ORCID 0000-0001-9984-5342
Henri-Jacques DelecluseGerman Cancer Research Centre (DKFZ) and Inserm, Unit F100/U1074, Heidelberg, Germany.ORCID 0000-0002-1744-6274
Stefan M WillemsDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Melvin L K ChuaDivisions of Radiation Oncology and Medical Sciences, National Cancer Centre, Singapore, Singapore.ORCID 0000-0002-1648-1473
Pierre BussonCNRS-UMR 9018-METSY, Gustave Roussy and Université Paris-Saclay, Villejuif, France.ORCID 0000-0003-1027-3400
Kwok Wai LoDepartment of Anatomical and Cellular Pathology and State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Hong Kong, China.ORCID 0000-0002-3488-6124
Guido WollmannInstitute of Virology and Christian Doppler Laboratory for Viral Immunotherapy of Cancer, Medical University of Innsbruck, Innsbruck, Austria.
Nischalan PillayUCL Cancer Institute, University College London, London, UK.ORCID 0000-0003-0579-4105
Bart VanhaesebroeckUCL Cancer Institute, University College London, London, UK. bart.vanh@ucl.ac.uk.ORCID 0000-0002-7074-3673
Valerie J LundUCL Cancer Institute, University College London, London, UK. v.lund@ucl.ac.uk.
CRUK Lung Cancer Centre of Excellence · GBInnsbruck Medical University · ATChinese University of Hong Kong · HKJinan University · CNUniversitas Gadjah Mada · IDNational Cancer Centre Singapore · SGRoyal London Hospital · GBStanford University · USUniversity of Oxford · GBBarts Health NHS Trust · GBDuke-NUS Medical School · SGGerman Cancer Research Center · DEUniversity of Hong Kong · HKAddenbrooke's Hospital · GBAgency for Science, Technology and Research · SGCancer Research UK · GBCentre National de la Recherche Scientifique · FRImperial College Healthcare NHS Trust · GBNational University of Singapore · SGQueen Mary University of London · GB
Funding
Characterization and Targeting the GDNF and Other Pathways in Salivary Stem CellsR01DE025227 · NIDCR · STANFORD UNIVERSITY · PI LE, QUYNH-THU XUAN, XIAO, NAN · 2015 to 2019
$2.0MAustrian Science Fund FWF I 3976Cancer Research UK 15965Cancer Research UK 18387Cancer Research UK 23900Cancer Research UK 25722Cancer Research UK C23338/A25722Department of HealthNIDCR NIH HHS R01 DE025227Versus Arthritis 20522Wellcome Trust
Abstract
Nasopharyngeal cancer (NPC), endemic in Southeast Asia, lacks effective diagnostic and therapeutic strategies. Even in high-income countries the 5-year survival rate for stage IV NPC is less than 40%. Here we report high somatostatin receptor 2 (SSTR2) expression in multiple clinical cohorts comprising 402 primary, locally recurrent and metastatic NPCs. We show that SSTR2 expression is induced by the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) via the NF-κB pathway. Using cell-based and preclinical rodent models, we demonstrate the therapeutic potential of SSTR2 targeting using a cytotoxic drug conjugate, PEN-221, which is found to be superior to FDA-approved SSTR2-binding cytostatic agents. Furthermore, we reveal significant correlation of SSTR expression with increased rates of survival and report in vivo uptake of the SSTR2-binding
Indexed as
Epstein-Barr Virus InfectionsGene Expression Regulation, NeoplasticNasopharyngeal CarcinomaNasopharyngeal NeoplasmsNeoplasm Recurrence, LocalReceptors, SomatostatinViral Matrix ProteinsAnimalsAntineoplastic AgentsCell Line, TumorFemaleHerpesvirus 4, HumanHost-Pathogen InteractionsHumansLymphatic MetastasisMaleAntineoplastic AgentsEBV-associated membrane antigen, Epstein-Barr virusNF-kappa BOctreotideReceptors, SomatostatinSSTR2 protein, humanViral Matrix Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.